At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 167 enrolled
Drug / intervention
bupivacaine liposome injectable suspension +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Double-Blind, Multicenter, Active-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of EXPAREL Admixed With Bupivacaine Hydrochloric Acid (HCl) vs. Bupivacaine HCl Administered Via Adductor Canal Block for Postsurgical Analgesia in Subjects Undergoing Primary Unilateral Total Knee Arthroplasty
In Brief
A Phase 3 clinical trial evaluating bupivacaine liposome injectable suspension and Bupivacaine Hydrochloride for Knee Osteoarthritis and Pain Management. Completed, enrolled 167 participants across 6 sites.
Detailed Summary
The purpose of the study is to compare magnitude of postsurgical analgesic effect in different groups following a single dose of study drug when administered via adductor canal block in subjects undergoing primary unilateral total knee arthroplasty.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKnee Osteoarthritis, Pain Management
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20222023202420252026
First PostedDec 2021
Enrollment StartJan 2022
Primary CompletionJul 2022
TodayJul 2026
First PostedDec 1, 2021
Enrollment StartJan 18, 2022
Primary CompletionJul 11, 2022
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 4.6 years ago
Interventions
bupivacaine liposome injectable suspensiondrug
Adductor canal block with EXPAREL
Bupivacaine Hydrochloridedrug
Adductor Canal Block with bupivacaine HCl